Hi
I was reading a
research paper relating to
Well I suspect you may not have much experience reading this sort of material. So let me put in a few pointers if I may.
Firstly its important to remember what journal you are reading from, this indicates its target audience. Then its important to understand what is being written about, this author isn't writing up research outcomes they are writing up their opinion of research outcomes in a Journal of Cardiology;
importantly not a journal of Thoracic Surgery.
In this update, a few issues are re-emphasized; however, the major thrust is on newer
findings that have had an impact on the choice of PHV.
The author apparently loves to put in "conclusions" on every section, suggesting that each section is unrelated to the others. Strange that there are 8 "conclusion" sections.
Conclusions. When comparing outcomes with different PHVs, it is important to: 1) ensure that the baseline characteristics of the patients and their comorbid conditions are the same, or are at least very similar, which can be best determined by a good prospective randomized trial (14); and 2) determine cause of death when comparing survival after PHV replacement.
that seems more like simply good advice to anyone who doesn't have a clue about research and trying to determine validity ... I wonder if he's talking about himself?
Conclusions. Mechanical PHVs that are approved by the Food and Drug Administration (FDA) and have good and comparable outcomes at >=15 to 20 years of follow-up will likely have good outcomes on very long-term follow-up.
really ... wow ... and pray tell which valves in replacement are used which are not approved by the FDA? Further which studies are actually available showing 15 to 20 year follow up? Please show me a few. Because all the ones I've seen that claim that have in the detail something like "
mean paitient follow up ~7.5 years" or something like that
Conclusions. In 2000, Ross advised the terminology “Ross procedure” should not be used because what surgeons are doing is not what he described; instead, it should be called the “Ross Principle”
not much of a conclusion, but I agree with this (and I'm as it happens no fan of the Ross and believe its got highly specific criteria where its successfull ... ask Arnie)
Conclusions. At present, the choice of PHV in most clinical situations is between a mechanical PHV and a stented bioprosthesis. An important determining factor in the choice between these 2 PHVs is which of the 2 complications, anticoagulation therapy or SVD, one wants to avoid.
I'm just going to FacePalm this one ... I think anyone who's read anything at all knows this. Its like PHV 101
Conclusions. Anticoagulants are essential with the use of mechanical valves, and can be instituted and maintained in many patients with low risk. The disadvantages include lifetime needs of therapy and tests, difficulties in initiating and maintaining an adequate INR in many patients, and major risks of bleeding
more PHV101, its like word salad and if anyone didn't know all of the above, then they should not be practicing.
Frankly so far I'd have just dumped this as word salad with a bunch of pretty pictures which are largely meaningless. So I'm not going to go citing and criticising his poor writing.
Some worthy mentions of weird is his use of combined metrics
What an outstandingly strange metric:
the risk or reoperation and major bleed all rolled into one metric (which should use OR not AND).
It's like the risk of car engine failure and flat tyre in a car.
Totally different and unrelated events. When you see something like that it's a red flag for either incompetency or a other agenda. I find it interesting how few cardiologists are actually interested in the nitty gritty of INR management. None I've met have ever even been involved with it, yet all are clear that Time in Therapeutic Range (TTR) is critical for good outcomes. The above seems to accept that there will not be adequate TTR and the ignored elephant in the room is "how can we improve TTR" ... Did I refer you to this presentation by a Dr Schaff from the Mayo?
if I didn't please grab a coffee and go through it. However the absolute minimum Too Long Didn't Read it is this bit:
So there you have a premier Thoracic Surgeon saying TTR is crucial for success in mech valves. Its so simple its ludicrus.
I'm going to point you at what we try to instil in our University undergraduates (in the USA there is this strange idea of calling Universities by two names, University (eg UCLA) a Colleges (can't think of a University that calls itself a College). In Australia we just call them Universities.
Critical thinking isn't just "Deny and rebuke everything" it is "Read, undertake a moments reflection and consider". Monash Uni has a great page (I didn't go to Monash, I've done degrees from other universities here in Queensland) on Critical Thinking
https://www.monash.edu/learnhq/enhance-your-thinking/critical-thinking/what-is-critical-thinking
What is critical thinking?
Critical thinking is not about being negative. The term critical comes from the Greek word kritikos meaning discerning. So critical thinking is a deeper kind of thinking in which we do not take things for granted but question, analyse and evaluate what we read, hear, say, or write. It is a general term used to identify essential mindsets and skills that contribute to effective decision making. While there are many definitions for critical thinking, here is one that covers its essential aspects:
In summary my opinion is that that paper was not even toilet worthy.
Lastly (since I mentioned the Ross) let me link you to an "critical analysis" I wrote up some years back to demonstrate the method of reading articles meant for scientific publication (
link).
I hope this helps.